Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 2/20 | 0.56 |
| ▸ | CCNK | O75909 | 15/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 15/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.52 |
| ▸ | CDK9 | P50750 | 14/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.52 |
| ▸ | CDK2 | P24941 | 13/20 | 0.52 |
| ▸ | CDK7 | P50613 | 3/20 | 0.50 |
| ▸ | CCNH | P51946 | 3/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25222649 | 1.00 | IDH2 (0.56) | IDH2CCNKCDK12CCNT1CDK9 | |
| SCHEMBL28312479 | 1.00 | IDH2 (0.56) | IDH2CCNKCDK12CCNT1CDK9 | |
| SCHEMBL28549701 | 0.91 | IDH2 (0.54) | IDH2CCNKCDK12CCNT1CDK9 | |
| SCHEMBL22895847 | 0.91 | IDH2 (0.54) | IDH2CCNKCDK12CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL28544501 | 0.90 | IDH2 (0.53) | IDH2CCNKCDK12CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL29777672 | 0.90 | IDH2 (0.53) | IDH2CCNKCDK12CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL28544495 | 0.90 | IDH2 (0.53) | IDH2CCNKCDK12CCNT1CDK9 | |
| SCHEMBL26126794 | 0.84 | IDH2 (0.40) | IDH2 | |
| SCHEMBL18607391 | 0.82 | ULK1 (0.55) | — | |
| SCHEMBL20145185 | 0.82 | IL1B (0.53) | IDH2CCNKCDK12CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024063670-A1 | CYCLIN-DEPENDENT KINASE 7 INHIBITORS | Акционерное общество "БИОКАД" | 2024-03-28 | — | — | WO | claimed |
| EP-4269402-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022134641-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 湃隆生物科技有限公司（香港） | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | IDH2 448/4885CCNK 17/4885CDK12 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.